Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE TRIAL: Pemvidutide in Alcohol-Associated Liver Disease
NCT07009860Phase 2Active, not recruiting
- Sponsor
- Altimmune, Inc.
- Start
- Jun 2025
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of pemvidutide in alcohol-associated liver disease (ALD), sponsored by Altimmune, Inc.. Started Jun 2025; status: active, not recruiting.
02
Drugs
pemvidutide
03
Conditions
alcohol-associated liver disease (ALD)
Beyond the preview
Go deeper on NCT07009860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009860.